<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02263248</url>
  </required_header>
  <id_info>
    <org_study_id>035/2014</org_study_id>
    <nct_id>NCT02263248</nct_id>
  </id_info>
  <brief_title>Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine</brief_title>
  <acronym>(IRLGREY-B)</acronym>
  <official_title>Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre for Addiction and Mental Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Reckitt Benckiser LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre for Addiction and Mental Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Investigators are conducting a research study to learn about the safety and benefit of&#xD;
      using a medication called buprenorphine for patient with difficult to treat depression . This&#xD;
      research study is testing whether combining two medications will be effective in treating&#xD;
      depression when initial treatment with just one antidepressant does not relieve the&#xD;
      depressive symptoms ; this is what is called &quot; difficult to treat depression &quot; or &quot; treatment&#xD;
      resistant depression &quot;. The two medication the investigators are using are &quot; an&#xD;
      anti-depressant medication called venlafaxine XR ( the generic form of Effexor ) and&#xD;
      buprenorphine . Buprenorphine is a medication that is FDA approved for the treatment of&#xD;
      opioid dependence. The investigators are testing whether adding buprenorphine to venlafaxine&#xD;
      enhances treatment response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to examine the feasibility, safety, and tolerability of&#xD;
      buprenorphine (BPN) as a novel treatment for late-life treatment resistant depression&#xD;
      (LL-TRD). The investigators aim to use a clinical trial methodology common to all three&#xD;
      sites, and to examine the mechanism of action (MOA) of BPN using translational neuroscience&#xD;
      methods. Over Â½ of seniors with depression fail to respond to traditional&#xD;
      antidepressants.19,20 Modulation of the opiate system with BPN offers a novel mechanistic&#xD;
      approach to improve the lives of patients with LL-TRD, with a safety profile potentially&#xD;
      superior to current augmentation strategies such as antipsychotics, lithium, ECT, and&#xD;
      surgical interventions (e.g., deep brain or vagal nerve stimulation).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">May 1, 2018</completion_date>
  <primary_completion_date type="Actual">January 19, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Montgomery-Asberg Depression Rating Scale</measure>
    <time_frame>32 weeks</time_frame>
    <description>MADRS at baseline will establish study eligibility and will assess treatment-sensitive change in MDD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Suicidal Ideation Scale ( SIS)</measure>
    <time_frame>32 weeks</time_frame>
    <description>Assess suicidal ideation and previous suicide attempts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Symptom Inventory for Anxiety</measure>
    <time_frame>32 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numeric Scale of Pain ( NRS-P)</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency, Intensity, and Burden of Side Effects Rating (FIBSER)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Assess overall burden or degree of interference in day-to-day activities and function due to the side effects attributable specifically to the antidepressant (in this case, buprenorphine) treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antidepressant Side Effect Checklist (ASEC)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Assessment of side- effects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>venlafaxine XR plus buprenorphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug Intervention: venlafaxine XR plus buprenorphine Dosage varies. Subject remains on antidepressant throughout the 32 week study. Will be randomized to buprenorphine or placebo for up to 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>venlafaxine XR plus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug Intervention: venlafaxine XR plus placebo Dosage varies . Subject remains on antidepressant throughout the 32 weeks study. Will be randomized to buprenorphine or placebo for up to 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>venlafaxine</intervention_name>
    <description>slow titration to a maximum of 300 mg per day. will remain on venlafaxine XR for upto 32 weeks.</description>
    <arm_group_label>venlafaxine XR plus buprenorphine</arm_group_label>
    <arm_group_label>venlafaxine XR plus placebo</arm_group_label>
    <other_name>Effexor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>buprenorphine</intervention_name>
    <description>randomized to either buprenorphine or placebo, dose range from 0.2 mg qd/ to 1.2 mg qd</description>
    <arm_group_label>venlafaxine XR plus buprenorphine</arm_group_label>
    <other_name>Temgesic</other_name>
    <other_name>Subutex</other_name>
    <other_name>Suboxone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>patients will remain on venlafaxine XR and be randomzied to receive either placebo or buprenorphine for 8 weeks. at the end of 8 weeks those who did not receive buprenorphine will be given an opportunity to try it.</description>
    <arm_group_label>venlafaxine XR plus placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 50 years&#xD;
&#xD;
          2. Major depressive disorder (MDD), single or recurrent, as diagnosed by the SCID-IV (or&#xD;
             SCID-5 if available)&#xD;
&#xD;
          3. MADRS &gt; 15&#xD;
&#xD;
          4. Has or agrees to establish a clinical relationship with primary care physician (PCP).&#xD;
&#xD;
          5. Availability of an informant (e.g., emergency contact) is encouraged but not required&#xD;
             for study participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to provide informed consent&#xD;
&#xD;
          2. Depressive symptoms not severe enough (i.e., MADRS &lt; 15) at the baseline assessments&#xD;
&#xD;
          3. Dementia, as defined by 3MS &lt; 80 and clinical evidence of dementia&#xD;
&#xD;
          4. Lifetime diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective&#xD;
             disorder, schizophreniform disorder, delusional disorder, or current psychotic&#xD;
             symptoms, as diagnosed by the SCID&#xD;
&#xD;
          5. Abuse of or dependence on alcohol or other substances within the past 3 months as&#xD;
             determined by SCID, and score of &gt; 8 on AUDIT-C and confirmed by study physician&#xD;
             interview&#xD;
&#xD;
          6. High risk for suicide (e.g., active SI and/or current/recent intent or plan) AND&#xD;
             unable to be managed safely in the clinical trial (e.g., unwilling to be&#xD;
             hospitalized). Urgent psychiatric referral will be made in these cases&#xD;
&#xD;
          7. Contraindication to venlafaxine or buprenorphine as determined by PCP and study&#xD;
             physician including history of intolerance of either venlafaxine or buprenorphine in&#xD;
             the study target dosage range (venlafaxine at up to 300 mg/day; buprenorphine at up to&#xD;
             1.2 mg/day)&#xD;
&#xD;
          8. Inability to communicate in English (i.e., interview cannot be conducted without an&#xD;
             interpreter; subject largely unable to understand questions and cannot respond in&#xD;
             English)&#xD;
&#xD;
          9. Non-correctable clinically significant sensory impairment (i.e., cannot hear well&#xD;
             enough to cooperate with interview)&#xD;
&#xD;
         10. Unstable medical illness, including delirium, uncontrolled diabetes mellitus,&#xD;
             hypertension, hyperlipidemia, or cerebrovascular or cardiovascular risk factors that&#xD;
             are not under medical management. This will be determined based on information from&#xD;
             the patient's personal physician and study physician's clinical judgment. Referral to&#xD;
             the patient's personal physician or to a general practitioner will be made in these&#xD;
             cases&#xD;
&#xD;
         11. Subjects taking psychotropic medications that cannot be safely tapered and&#xD;
             discontinued prior to study initiation. The following exceptions are allowed if they&#xD;
             have been taken at a stable dose for at least 4 weeks prior to study entry and there&#xD;
             is not a plan to change the dose during the next 32 -36 weeks: benzodiazepines up to 2&#xD;
             mg/d lorazepam equivalent; other sedative-hypnotics (e.g., zolpidem, zaleplon,&#xD;
             eszopiclone); gabapentin if prescribed for non-psychiatric indication (e.g.,&#xD;
             neuropathy)&#xD;
&#xD;
         12. History of opiate abuse or dependence&#xD;
&#xD;
         13. Severe pain, defined as &gt; 7 on 0-10 numeric rating scale for pain&#xD;
&#xD;
         14. Concomitant use of strong or moderate CYP3A4 inhibitor (indinavir, nelfinavir,&#xD;
             ritonavir, clarithromycin, itraconazole, ketonazole, nefazodone, saquinovir,&#xD;
             telithromycin, aprepitant, erythromycin, fluconazole, grapefruit juice, verapamil,&#xD;
             diltiazem)&#xD;
&#xD;
         15. Refusal to stop all opioids (to avoid precipitating opioid withdrawal)&#xD;
&#xD;
         16. Refusal to discontinue all alcohol (to reduce the risk of respiratory depression)&#xD;
&#xD;
         17. Hepatic impairment (AST/ALT &gt; 1.5 times upper normal)&#xD;
&#xD;
         18. Estimated Glomerular Filtration Rate (GFR) &lt; 20 ml/min&#xD;
&#xD;
         19. Inability/refusal to identify a person as an emergency contact&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel M Blumberger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CAMH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Addiction and Mental Health</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6J1H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>October 8, 2014</study_first_submitted>
  <study_first_submitted_qc>October 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2014</study_first_posted>
  <last_update_submitted>July 24, 2018</last_update_submitted>
  <last_update_submitted_qc>July 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre for Addiction and Mental Health</investigator_affiliation>
    <investigator_full_name>Daniel Blumberger</investigator_full_name>
    <investigator_title>Dr. Daniel. M. Blumberger</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

